Have Questions About COVID-19 Tests? Here Are Some Answers


As the highly contagious Omicron variant continues to spread, more and more people are thinking about getting tested for COVID-19. You may be feeling under the weather, or you may have recently spent time with someone who has COVID-19. You may want to get tested before seeing family or friends, or attending a large indoor gathering.

With a number of different tests available, many people have questions about which test to take, when to take it, and what their results may mean. In this Q&A, Aaron E. Glatt, MD, MACP, FIDSA, FSHEA, Chair of the Department of Medicine and Chief of Infectious Diseases at Mount Sinai South Nassau, explains how you can decide which test may meet your needs.

What types of tests are available? What are the differences between them?

There are a number of different ways that we can diagnose a COVID-19 infection. None of them are perfect, and each has their benefits and disadvantages. Let’s break it into two groups of testing: We have antigen tests, and we have PCR tests. Each of them has a role, and each of them has a slightly different situation where they may be preferable.

So we start off with the antigen test. This is what most people use at home. These are the tests you can buy at your local pharmacy. They are often referred to as “rapid tests.” If an at-home test is positive, and you are symptomatic, it’s highly likely that you have a COVID-19 infection. If you are taking this test because you’ve been exposed to somebody with COVID-19, it is also likely that a positive test is reliable. On the other hand, when these tests are negative, they’re just not good enough to necessarily rule out that a person does not in fact have COVID.

The other type of test is a PCR test. There are many different types of PCR tests. Most PCR tests will take 24 to 48 hours to return your results. PCR tests are somewhat more sensitive than rapid antigen tests.  If your PCR test result is positive, that will almost always represent a true positive, meaning it is accurate and you do have COVID-19 or that you had it in the recent past. The issue with these tests, however, is that they’re so specific. That means they can remain positive even when somebody is no longer contagious, and they no longer have COVID-19. But in general, the PCR tests are very good. They can tell you with a little bit more certainty that you did have an exposure to COVID-19.

How do I know which test I should take?

We usually recommend you talk to your health care provider if you’re concerned that you may have COVID-19. If you have symptoms or if you were exposed to COVID, then you may want to go get an at-home rapid test. If your rapid test is positive, you should talk to your doctor to decide what, if any, additional tests need to be done. If you have more serious symptoms, you should be evaluated by a doctor no matter what the antigen or PCR test shows.

When should I get tested?

If you have symptoms, you should get tested right away. If you’re being tested because of an exposure, we usually recommend waiting at least two days, or 48 hours, before testing. There are always exceptions to the rule. But that’s the general recommendation.

How reliable are at-home tests?

There are different at-home tests, and some of them are more reliable than others. If you have symptoms, or you think there’s a likelihood that you do in fact have COVID, then these tests can be very useful if they’re positive.

If my test result is positive, what should I do?

The first thing to do is contact your doctor. This could be a telehealth visit. We want you reaching out to your provider and getting expert medical advice from the person who knows you and your medical history. Not everyone has the same level of risk. It’s best to have a health care provider decide what evaluation needs to be done, and what potential treatments, additional testing, and ongoing monitoring you may need.

If my test result is positive, when should I retest?

There isn’t necessarily a reason to retest if you’re positive and your clinical care is being handled and you’re doing better. Typically, we wait a certain length of time to decide that a person is no longer contagious, and that they can stop isolating. That may be a five day period of time, assuming your symptoms are resolving and you have no fever. After that, we recommend that you be extremely careful in terms of distancing and wearing a mask whenever you’re going indoors among other people for at least an additional five days. For somebody who’s having a little bit more of a complicated clinical course—for example, they are having symptoms that aren’t resolving or they’re having persistent fevers—then you can’t assume that in five days, they’re no longer contagious. This should be something that your doctor helps you decide based upon your particular symptoms and medical history.

If my test result is negative, does that mean I’m good to go?

Anyone who has symptoms should not be going into public gatherings with other people. If they do have to go indoors, they should be wearing a mask and distancing as much as possible. A negative test doesn’t mean you don’t have COVID, and it doesn’t mean you can’t be contagious. Even if it’s not COVID, it might be the flu or some other virus that could be contagious to other people. As a result, you should really try and protect everybody from whatever illness you may have.

If I have symptoms, but my test was negative, what should I do?

In that situation, there are additional tests that you can take, such as testing for the flu or additional testing for COVID-19. You should talk to your doctor if you have ongoing symptoms and you have a negative COVID test. It can be a telehealth discussion. You should speak with your doctor, who knows you, and knows your background and your risk factors for serious illness.

Why are testing and vaccination still important?

It’s very important that patients realize that while the press reports that Omicron is a mild illness—you just get a little bit of flu-like symptoms, and you’re fine—that’s not really true for everybody. If you’re not vaccinated, Omicron can cause severe illness. Even in vaccinated people, if they’re not boosted, they are still more likely to get into trouble. So the best recommendation at this point is to get a booster dose of the vaccine if you’ve gotten vaccinated, and certainly, if you haven’t been vaccinated, this is still a great time to get vaccinated.

A misconception is that the vaccines don’t work because there are breakthrough infections. Nothing can be further from the truth. These vaccines are phenomenally successful in preventing death, in preventing serious illness, in preventing admissions to the hospital. Omicron, while “milder” than the Delta variant, can still cause all of these things for some people. It’s critically important for everyone to protect themselves, protect their loved ones, and protect their community by getting vaccinated.

Icahn School of Medicine at Mount Sinai: Annual State of the School Celebrates Research, Education, and Service to the Community


The annual State of the School was presented on Wednesday, January 26, by Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean, Icahn School of Medicine at Mount Sinai, and President for Academic Affairs, Mount Sinai Health System.

The annual presentation provides an update on Icahn Mount Sinai’s recent accomplishments in advancing medical research, educating the future leaders of health care, and serving the community. During the second year of the COVID-19 pandemic, the presentation was again delivered on video.  It can be viewed here.

The State of the School included initiatives aimed at improving the lives of patients, which include new areas of investment in research and newly established Institutes, Departments, and Centers. Dr. Charney also highlighted the School’s focus on innovation and entrepreneurship, and efforts to make Icahn Mount Sinai a more equitable and anti-racist institution.

The past year included new opportunities for the members of the Icahn Mount Sinai community to support patients and the advancement of medicine. During the State of the School, there was a video tribute to the heroes within the School who contributed to Mount Sinai’s COVID-19 response.

Leadership Updates for the Department of Neurosurgery

The Department of Neurosurgery has announced promotions and appointments of faculty members across Mount Sinai Health System.

J Mocco, MD, MS

J Mocco, MD, MS, has been promoted to Senior Vice Chair of Neurosurgery, Mount Sinai Health System.

In this new position, Dr. Mocco will work with the Department Chair and clinicians to provide strategic leadership in advancing the Department of Neurosurgery’s 10 service lines across the Health System. These include cerebrovascular, skull base, malignant brain tumors, pituitary/neuroendocrine, spine, neuromodulation, epilepsy, pediatrics, trauma, and neurocritical care.

Since joining the Department, Dr. Mocco has served as Vice Chair of Neurosurgery and Director of the Neurosurgery Residency Program. He is Director of the Cerebrovascular Center and Co-Director of the Neuroendovascular Fellowship Program. In these roles, Dr. Mocco developed the stroke coverage model for NYC Health + Hospitals/Elmhurst and the Mount Sinai Queens stroke suite program. This initiative established a novel care pathway that is already delivering dramatic improvements for stroke care. Dr. Mocco has also directed the opening of thrombectomy and diagnostic neurointerventional services at Mount Sinai Brooklyn. He has gained international recognition for his extensive stroke research as a key thought leader and Principal Investigator in many pivotal clinical trials.

Dr. Mocco received his medical degree from the Columbia University College of Physicians and Surgeons. He completed his Master of Science in Biostatistics at the Mailman School of Public Health at Columbia University, a residency in neurological surgery at the Neurological Institute of New York, and a fellowship in endovascular neurosurgery at the University of Buffalo.

Isabelle M. Germano, MD, MBA

Isabelle M. Germano, MD, MBA, is Vice Chair of Faculty Affairs for the Department of Neurosurgery, Mount Sinai Health System. Dr. Germano received her medical degree from the University of Turin Medical School and completed residencies/fellowships at the University of California, San Francisco, the Albert Einstein College of Medicine, the University of Zurich, and the Montreal Neurological Institute. Dr. Germano received her MBA from the New York University Stern School of Business.

 

 

 

 

 

Raj K. Shrivastava, MD

Raj K. Shrivastava, MD, has been appointed Vice Chair for Education, Department of Neurosurgery, Mount Sinai Health System, and Director of the Neurosurgery Residency Program at the Icahn School of Medicine at Mount Sinai. Dr. Shrivastava will oversee educational programs throughout the Department of Neurosurgery, including residency and fellowship programs and medical student education and sub-internships. As residency program Director, he will manage the seven-year-long program’s curriculum and establish additional activities that further enrich the experience of the department’s 14 residents both in and out of the operating room. He will also spearhead initiatives and strategies to increase the program’s national exposure and reputation.

Dr. Shrivastava, who previously served as Associate Program Director of the Residency Program, earned his medical degree from the University of Pennsylvania, followed by a residency in neurosurgery at The Mount Sinai Hospital and a fellowship in skull base surgery at Mount Sinai.

Johanna T. Fifi, MD

Johanna T. Fifi, MD, has been appointed Co-Director of the Pediatric Cerebrovascular Disorders Program and Site Director of Cerebrovascular Services at Mount Sinai West. Dr. Fifi will be responsible for continuing to provide world-class care in the diagnosis, treatment, management, and research of pediatric brain vascular malformations, head and neck vascular malformations, aneurysms, and occlusive vascular diseases. She will also be responsible for providing clinical and technical leadership in the development and expansion of Mount Sinai West’s cerebrovascular neurosurgical services, including treating strokes, aneurysms, vascular malformations, and intracerebral hemorrhage. She joined the program as a part of Continuum Health Partners in 20

Women With Disabilities Experience Barriers to Access and Disparities in Health Care

Arianny Ramirez, right, a Clinical Research Coordinator in the Spinal Cord Injury Program at The Mount Sinai Hospital, demonstrates patient care in a staff training video with physical therapist Alexandra McGivern.

Intersectionality is a crucial consideration as providers treat patients and understand their needs inside and outside health care facilities, said Arianny Ramirez, a Clinical Research Coordinator in the Spinal Cord Injury Program at The Mount Sinai Hospital, who was the featured speaker for a virtual talk hosted by the Office for Diversity and Inclusion (ODI) at Mount Sinai. The session, “Health Care Disparities and Women with Disabilities,” is available here.

The talk was part of the Raising Disability Awareness Virtual Talk Series, launched by ODI in 2020 for Disability Awareness Month, featured speakers from around the Mount Sinai Health System and the community to promote an inclusive and equitable workplace and health care environment for people with disabilities.

Arianny Ramirez

Ms. Ramirez, a woman of color with a physical disability, discussed health care challenges at both a personal level and a population level. She said the health care community must work together to understand the intersection of sexism, racism, and ableism, and its effect on women with disabilities. “The biggest obstacles I face in my life as a woman with a disability are the barriers and limits society places on me,” she said.

After an accidental fall that paralyzed her from the waist down at age 18, Mrs. Ramirez realized that her life and the lives of many others would be easier if the world were designed with disabilities in mind.

According to the Centers for Disease Control and Prevention, about 36 million women in the United States have disabilities. This number is expected to continue growing, says Mrs. Ramirez, and “women with disabilities face more difficulty than women without disabilities in accessing health care screenings.” Routine physical exams, mammogram, Pap smears, sexually transmitted infection (STI) testing, and eye exams are just a few of the screenings that are more challenging to access for women with disabilities.

Physical and attitudinal barriers often prevent this population from seeking and receiving equitable and appropriate health care. The necessary equipment, machinery, and devices to care for these women are not always present in doctors’ offices, Mrs. Ramirez said of clinical care in the United States.

Additionally, stereotypes and discrimination are often directed toward people with disabilities in health care settings, making them feel uncomfortable and excluded, and there are limited training and guidelines in place to address the specific needs of women with disabilities.

“Let’s start with our physical barriers,” Mrs. Ramirez said. “They consist of a lack of adaptive examination tables and scales, inaccessible testing rooms, and inaccessible diagnostic equipment. Over 90 percent of physicians’ offices do not have wheelchair-accessible scales.”

The Mount Sinai Health System is working to address these disparities with a variety of measures, including a course created by the Department of Rehabilitation and Human Performance for Mount Sinai physicians and other providers in fields such as family medicine, internal medicine, obstetrics and gynecology, and emergency medicine. Mount Sinai employees can register for the course, “Improving Health Care Access for Women with Spinal Cord Injury” on Mount Sinai’s PEAK site.

Mount Sinai’s Spinal Cord Injury Research Center also offers information to the public about support groups, exercise, and clinical trials, including one addressing access for women with spinal cord injuries.

Ultimately, Mrs. Ramirez called for the public to consider the world from a different perspective.

“I invite all of you to just look around your environment. Whether it’s in the office, the structure that you live in, you work in, or your commute, and think ‘what if I did have a disability? What if I did have knee surgery and there wasn’t a lip in the sidewalk that I couldn’t get over or something?’” she said. “Be mindful of the experiences other people are having and remember that a disability can happen to anyone. One can become disabled at any point in your life, and you can be a part of this community in the future as well. If you do your part and advocate for structural change, this can improve the environment around us and open the door for women with disabilities to get the care they need and live their lives.”

Speaking as a woman with a disability and a professional in rehabilitation, Ms. Ramirez called on  the health care community to take four measures: Increase professional education, training, and technical assistance so providers understand disability cultural competency; implement new monitoring and accountability laws and practices to increase oversight; use accreditations to ensure health care facilities comply with accessibility guidelines; and create a universal design that can be applied to any facility to care for and welcome people with disabilities uniformly.

“Until ableism becomes a conscious thought in nondisabled people’s minds, only then will true equality be achieved,” she said.

Mount Sinai West Earns National Accolades for Obstetrical Care

Mount Sinai West earned a High Performing rating, the highest rating available, from U.S. News & World Report in the publication’s inaugural assessment of hospitals that provide obstetrical care. Mount Sinai West, along with Mount Sinai Morningside, which are ranked together, are among 237 of 2,700 hospitals in the United States to receive this rating.

To achieve the High Performing rating for maternity care, hospitals had to excel on multiple metrics that are important to families, including complication rates, C-section rates, whether births were scheduled too early in pregnancy, and breast feeding support for new parents.

Mount Sinai West has a culture that prioritizes low-intervention births and shared decision-making between providers and their pregnant patients and has a longstanding tradition of using midwives. Examples of how the hospital puts this into practice include offering nitrous oxide as an alternative pain-control measure to an epidural and wireless monitoring that enables patients to walk around during labor rather than having to stay in bed.

The labor and delivery unit’s providers are also trained in TeamSTEPPS, a teamwork model developed by the U.S. Department of Defense and the Agency for Healthcare Research and Quality, to optimize patient outcomes by improving communication among providers.

“We are proud to be included in the inaugural edition of Best Hospitals for Maternity Care,” says Holly Loudon, MD, MPH, Site Chair, Obstetrics, Gynecology and Reproductive Medicine, Mount Sinai West.  “To be recognized on a national level is a tribute to our outstanding team of obstetrical faculty, nursing staff, and support staff and their dedication to quality, safety, and patient experience.”

Advancing Artificial Intelligence Through Philanthropy

David Windreich

Thanks to the outstanding generosity of the Windreich Family Foundation, the Icahn School of Medicine at Mount Sinai will advance its vision of integrating Artificial Intelligence (AI) and machine learning into research and clinical practice to amplify patient-centered care. This multi-million dollar gift will establish the Windreich Department of Artificial Intelligence and Human Health at Mount Sinai.

By establishing one of the first departments devoted to AI in a medical school, this gift represents Mount Sinai’s exceptional commitment to integrating AI throughout the Mount Sinai Health System. It will enable the recruitment of dedicated faculty, novel research initiatives, and the acquisition of any equipment and software that are mission critical to ensuring Mount Sinai continues to lead bold initiatives that embrace the power of technology to accelerate advances in both scientific research and clinical care.

Oversight of the newly named Windreich Department of Artificial Intelligence and Human Health will fall under the purview of its inaugural Chair, Thomas J. Fuchs, Dr.sc, who is also the Co-Director of the Hasso Plattner Institute for Digital Health at Mount Sinai. The new department was formed under the vision and guidance of Dennis S. Charney, MD, the Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine. “This gift will ensure Mount Sinai continues to be at the forefront of the AI-driven revolution of health care to the benefit of Mount Sinai’s diverse patient population,” says Dr. Charney.

“Our duty at the new department at Mount Sinai is to ensure that our patients are the main beneficiaries of the enormous impact AI will have on health care,” says Dr. Fuchs.  “To realize this vision, we are tremendously grateful for the gift from the Windreich Family Foundation. Mr. Windreich’s forward looking support will allow us to build a unique AI infrastructure at Mount Sinai and attract the world’s leading talent in this space.”

David Windreich, who serves on the Boards of Trustees at Mount Sinai, has a history of supporting AI and big data solutions in health care. His philanthropy extends to naming the Windreich Center for Bioinformatics at Mount Sinai. This Center is singularly focused on developing cutting-edge, web-based software tools and databases to facilitate the collection and analysis of diverse and complex data from human cells and tissues that will inform precise treatments for patients based on their unique genetic makeup. Mr. Windreich is also a former member of the Board of Directors for Sema4, a platform that uses machine learning and AI tools to analyze a database of more than 10 million patient genomic profiles and clinical records. Sema4 spun out of Mount Sinai in 2017 and went public at a $3 billion valuation in 2021.

“We have not yet reached the tipping point of how AI can play a major role in health care,” says Mr. Windreich. “My family is excited to play a role in supporting Mount Sinai’s initiative of being at the forefront of delivering technology solutions that will ultimately improve care and save lives.”

Pin It on Pinterest